Safety and Immunogenicity of 2-dose Inactivated COVID-19 Vaccine in Kidney Transplant Recipients

West China Hospital300 enrolled

Overview

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has a major impact on transplant recipients, with mortality rates up to 20%. However, immunocompromised individuals have been excluded from studies of SARS-CoV-2 vaccines. In such patients, the immune response to vaccination may be blunted. To better understand the immunogenicity of SARS-CoV-2 vaccines in transplant recipients, we quantified the humoral response to SARS-CoV-2 vaccine in kidney transplant recipients.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Kidney Transplantation SARS-CoV-2 Acute Respiratory Disease Vaccine

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: Receiving kidney transplantation in West China Hospital, Sichuan University Exclusion Criteria: 1\) History of rejection or infection over the previous 3 months; 2) receiving kidney transplantation \>3 months; 3) Combined with HBV/HVC/HIV infection in the donor or recipient; 4) Malignancy history in the donor and recipient; 5) organ transplant history in the recipient.

Outcomes

Primary Outcomes

seropositive anti-COVID-19 antibody

seropositive anti-COVID-19 antibody, including IgM, IgG, and IgA

Time frame: 2 to 6 weeks after the second injection of inactivated vaccine